Literature DB >> 21717081

Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas.

Olivera J Finn1, Kira R Gantt, Andrew J Lepisto, Sharmila Pejawar-Gaddy, Jia Xue, Pamela L Beatty.   

Abstract

Many important aspects of cancer biology, such as cancer initiation, progression, and metastasis, have been studied in animal models, mostly mice. As long as cancer was considered primarily a genetic disease, the study of transplantable mouse tumors, or even human tumor xenografts in immunocompromised mice, appeared to suffice. Many important genetic events that lead to transformation and in vivo tumor growth were elucidated. However, many even more important factors that determine whether or not the genetic potential of a tumor cell will be realized, such as the host response to the tumor and the tumor microenvironment that influences this response over a long period of time of tumor development, remained untested and unappreciated. This is slowly changing with the advent of molecular techniques that have spurred efforts to engineer better mouse models of human tumors. In this review, we show results of our efforts to combine a genetic mouse model of spontaneous human adenocarcinomas based on a Kras mutation, with an important human molecule MUC1 that is abnormally expressed on human adenocarcinomas, promoting oncogenesis, proinflammatory tumor microenvironment, and immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717081     DOI: 10.1007/s12026-011-8214-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  19 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

3.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

4.  Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.

Authors:  Pamela L Beatty; Sowmya Narayanan; Jean Gariépy; Sarangarajan Ranganathan; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

5.  RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells.

Authors:  Hideaki Tsutsumida; Benjamin J Swanson; Pankaj K Singh; Thomas C Caffrey; Shinichi Kitajima; Masamichi Goto; Suguru Yonezawa; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

6.  Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling.

Authors:  Jian Ren; Yongqing Li; Donald Kufe
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

7.  Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways.

Authors:  Eric J Thompson; Kandavel Shanmugam; Christine L Hattrup; Kari L Kotlarczyk; Albert Gutierrez; Judy M Bradley; Pinku Mukherjee; Sandra J Gendler
Journal:  Mol Cancer Res       Date:  2006-07       Impact factor: 5.852

8.  MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.

Authors:  Katja Engelmann; Hongmei Shen; Olivera J Finn
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

9.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

Authors:  Y Li; A Bharti; D Chen; J Gong; D Kufe
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  MUC1* mediates the growth of human pluripotent stem cells.

Authors:  Sherry T Hikita; Kenneth S Kosik; Dennis O Clegg; Cynthia Bamdad
Journal:  PLoS One       Date:  2008-10-03       Impact factor: 3.240

View more
  17 in total

Review 1.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

Review 2.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Authors:  Elizabeth Scheid; Pierre Major; Alain Bergeron; Olivera J Finn; Russell D Salter; Robin Eady; Bader Yassine-Diab; David Favre; Yoav Peretz; Claire Landry; Sebastien Hotte; Som D Mukherjee; Gregory A Dekaban; Corby Fink; Paula J Foster; Jeffery Gaudet; Jean Gariepy; Rafick-Pierre Sekaly; Louis Lacombe; Yves Fradet; Ronan Foley
Journal:  Cancer Immunol Res       Date:  2016-09-07       Impact factor: 11.151

4.  Effect of rosemary polyphenols on human colon cancer cells: transcriptomic profiling and functional enrichment analysis.

Authors:  Alberto Valdés; Virginia García-Cañas; Lourdes Rocamora-Reverte; Angeles Gómez-Martínez; José Antonio Ferragut; Alejandro Cifuentes
Journal:  Genes Nutr       Date:  2012-08-25       Impact factor: 5.523

5.  Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients.

Authors:  Carlo Fremd; Stefan Stefanovic; Philipp Beckhove; Maria Pritsch; Hendry Lim; Markus Wallwiener; Joerg Heil; Michael Golatta; Joachim Rom; Christof Sohn; Andreas Schneeweiss; Florian Schuetz; Christoph Domschke
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

6.  Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Authors:  Avery D Posey; Robert D Schwab; Alina C Boesteanu; Catharina Steentoft; Ulla Mandel; Boris Engels; Jennifer D Stone; Thomas D Madsen; Karin Schreiber; Kathleen M Haines; Alexandria P Cogdill; Taylor J Chen; Decheng Song; John Scholler; David M Kranz; Michael D Feldman; Regina Young; Brian Keith; Hans Schreiber; Henrik Clausen; Laura A Johnson; Carl H June
Journal:  Immunity       Date:  2016-06-21       Impact factor: 31.745

Review 7.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

Review 8.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

10.  Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).

Authors:  Concetta Ragone; Carmen Manolio; Beatrice Cavalluzzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Filippo Castiglione; Luigi Vitagliano; Emanuela Iaccarino; Menotti Ruvo; Maria Tagliamonte; Luigi Buonaguro
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.